Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis

BACKGROUND: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has been used to treat patients with diffuse large B-cell lymphoma (DLBCL) under National Health Insurance (NHI) scheme in Indonesia. This study aims to estimate its cost-effectiveness and budget impact. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Putri, Septiara, Setiawan, Ery, Saldi, Siti Rizny F., Khoe, Levina Chandra, Sari, Euis Ratna, Megraini, Amila, Nadjib, Mardiati, Sastroasmoro, Sudigdo, Armansyah, Armansyah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040215/
https://www.ncbi.nlm.nih.gov/pubmed/35468783
http://dx.doi.org/10.1186/s12913-022-07956-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040215/
https://www.ncbi.nlm.nih.gov/pubmed/35468783
http://dx.doi.org/10.1186/s12913-022-07956-w

Ejemplares similares